Summary
This consensus paper, published in the Journal of the American College of Cardiology in 2017, proposes standardised neurological endpoints for cardiovascular clinical trials. Authored by a large international group of cardiologists, neurologists, and neuroradiologists, the work addresses the heterogeneity in how neurological complications—particularly stroke and cognitive impairment—have been assessed across cardiology studies. The authors recommend harmonised measurement protocols to improve comparability and statistical power in detecting brain-related adverse events associated with cardiovascular procedures and interventions.
Regional applicability
The proposed standardised endpoints would support UK-based cardiovascular research and clinical trials, facilitating alignment with international trial protocols and enabling more robust comparative effectiveness analyses. These recommendations are particularly relevant for NHS-funded cardiovascular research networks and cardiac intervention centres monitoring patient safety outcomes.
Key measures
Neurological assessment protocols; cognitive testing batteries; stroke severity scales; endpoints for neurocognitive injury in cardiovascular interventions
Outcomes reported
The paper proposes standardised neurological endpoints for use in cardiovascular clinical trials, addressing the need for consistent assessment of neurological complications and cognitive outcomes. It reviews existing neurological assessment tools and recommends harmonised protocols for detecting stroke, cognitive decline, and other brain-related adverse events in cardiology populations.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.